Gilead Sciences, Inc.
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Zydelig (idelalisib by Quarter
Zydelig (idelalisib — hematologic oncology, legacy breakout) ($M) ($M)
Gilead Sciences Zydelig (idelalisib: $12M in Q4 2021, down 29.4% from a year earlier. That is the lowest of the 20 quarters on record here. No newer figure appears in the documents we track.
Where the Q4 2021 figure comes from
Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)
Source: Form 10-K (filed 2022-02-23) ↗
Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Zydelig (idelalisib — hematologic oncology, legacy breakout) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2021 | Dec 31, 2021 | 12 | -29.4% | Form 10-K (filed 2022-02-23) ↗ |
| Q3 2021 | Sep 30, 2021 | 13 | -23.5% | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2021 | Jun 30, 2021 | 22 | +22.2% | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 15 | -25.0% | Form 10-Q (filed 2021-05-06) ↗ |
| Q4 2020 | Dec 31, 2020 | 17 | -29.2% | Form 10-K (filed 2022-02-23) ↗ |
| Q3 2020 | Sep 30, 2020 | 17 | -34.6% | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2020 | Jun 30, 2020 | 18 | -30.8% | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2020 | Mar 31, 2020 | 20 | -25.9% | Form 10-Q (filed 2020-05-06) ↗ |
| Q4 2019 | Dec 31, 2019 | 24 | -41.5% | Form 10-K (filed 2022-02-23) ↗ |
| Q3 2019 | Sep 30, 2019 | 26 | +30.0% | Form 10-Q (filed 2019-11-05) ↗ |
| Q2 2019 | Jun 30, 2019 | 26 | -33.3% | Form 10-Q (filed 2019-08-06) ↗ |
| Q1 2019 | Mar 31, 2019 | 27 | -18.2% | Form 10-Q (filed 2020-05-06) ↗ |
| Q4 2018 | Dec 31, 2018 | 41 | +5.1% | Form 10-K (filed 2021-02-25) ↗ |
| Q3 2018 | Sep 30, 2018 | 20 | -50.0% | Form 10-Q (filed 2019-11-05) ↗ |
| Q2 2018 | Jun 30, 2018 | 39 | +11.4% | Form 10-Q (filed 2019-08-06) ↗ |
| Q1 2018 | Mar 31, 2018 | 33 | -5.7% | Form 10-Q (filed 2019-05-08) ↗ |
| Q4 2017 | Dec 31, 2017 | 39 | – | Form 10-K (filed 2019-02-26) ↗ |
| Q3 2017 | Sep 30, 2017 | 40 | – | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2017 | Jun 30, 2017 | 35 | – | Form 10-Q (filed 2018-08-06) ↗ |
| Q1 2017 | Mar 31, 2017 | 35 | – | Form 10-Q (filed 2018-05-09) ↗ |
Breakdown
What makes up zydelig (idelalisib
Cite this data
StockData. (2026). Gilead Sciences Zydelig (idelalisib ($M), quarterly Q1 2017–Q4 2021 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/other-zydelig
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.